Neuromyelitis Optica Research Articles

Abnormal functional connectivity of white-matter networks and gray-white matter functional networks in patients with NMOSD

Cognitive impairment (CI) has been reported in 29–70% of patients with neuromyelitis optica spectrum disorder (NMOSD). Abnormal white matter (WM) functional networks that correlate with cognitive functions have not been studied well in patients with NMOSD. The aim of the current study was to investigate functional connectivity (FC), spontaneous activity, and functional covariance connectivity (FCC) abnormalities of WM functional networks in patients with NMOSD and their correlation with cognitive performance. Twenty-four patients with NMOSD and 24 healthy controls (HCs) were included in the study. Participants underwent brain resting-state functional magnetic resonance imaging (fMRI) and the Montreal Cognitive Assessment (MoCA). Eight WM networks and nine gray matter (GM) networks were created. In patients, WM networks, including WM1–4, WM1–8, WM2–6, WM2–7, WM2–8, WM4–8, WM5–8 showed reduced FC (P < 0.05). All WM networks except WM1 showed decreased spontaneous activity (P < 0.05). The major GM networks demonstrated increased/decreased FC (P < 0.05), whereas GM7-WM7, GM8-WM4, GM8-WM6 and GM8-WM8 displayed decreased FC (P < 0.05). The MoCA results showed that two-thirds (16/24) of the patients had CI. FC and FCC in WM networks were correlated negatively with the MoCA scores (P < 0.05). WM functional networks are multi-layered. Abnormal FC of WM functional networks and GM functional networks may be responsible for CI.

Long-term Efficacy of Satralizumab in Patients with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Updated Analysis from the Open-label SAkuraMoon Study (S32.002)

Long-term Efficacy of Satralizumab in Patients with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Updated Analysis from the Open-label SAkuraMoon Study (S32.002)

Descriptive Analysis of Clinical Presentation in a Caribbean Hispanic Population with Neuromyelitis Optica Spectrum Disorders (NMO-SD) (P10-14.017)

Descriptive Analysis of Clinical Presentation in a Caribbean Hispanic Population with Neuromyelitis Optica Spectrum Disorders (NMO-SD) (P10-14.017)

Depression and Anxiety in Neuromyelitis Optica Spectrum Disease (NMOSD): Analysis of a National Dataset (P10-14.007)

Depression and Anxiety in Neuromyelitis Optica Spectrum Disease (NMOSD): Analysis of a National Dataset (P10-14.007)

Racial and Ethnic Disparities in the Incidence of Neuromyelitis Optica Spectrum Disorder (P4-4.002)

Racial and Ethnic Disparities in the Incidence of Neuromyelitis Optica Spectrum Disorder (P4-4.002)

Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment (S32.005)

Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment (S32.005)

Validation Process of NMOSDCopilotTM, a Software as a Medical Device (SaMD) for Patients Living with Neuromyelitis Optica Spectrum Disorder (P10-14.001)

Validation Process of NMOSDCopilotTM, a Software as a Medical Device (SaMD) for Patients Living with Neuromyelitis Optica Spectrum Disorder (P10-14.001)

Efficacy of Eculizumab in Acute Refractory Pediatric Neuromyelitis Optica: A Case Report (P11-14.012)

Efficacy of Eculizumab in Acute Refractory Pediatric Neuromyelitis Optica: A Case Report (P11-14.012)

Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in AntiCD20 Treated Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder (P8-6.006)

Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in AntiCD20 Treated Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder (P8-6.006)

Associations of the Circulating Levels of Cytokines with Risk of Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study (P11-14.004)

Associations of the Circulating Levels of Cytokines with Risk of Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study (P11-14.004)

Evaluation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels During Eculizumab and Ravulizumab Treatments in Aquaporin-4-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (S32.004)

Evaluation of Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) Levels During Eculizumab and Ravulizumab Treatments in Aquaporin-4-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (S32.004)

Transient Neutrophilic Pleocytosis and Hypoglycorrhachia in a Case of Neuromyelitis Optica Spectrum Disorder (P10-14.012)

Transient Neutrophilic Pleocytosis and Hypoglycorrhachia in a Case of Neuromyelitis Optica Spectrum Disorder (P10-14.012)

Neuromyelitis Optica Spectrum Disorders: A Preliminary Study of 33 Cases at the Neurology Department of Fann Teaching Hospital in Dakar (Senegal) (P8-6.003)

Neuromyelitis Optica Spectrum Disorders: A Preliminary Study of 33 Cases at the Neurology Department of Fann Teaching Hospital in Dakar (Senegal) (P8-6.003)

Comparison of Depression and Anxiety in Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis Patients: Analysis of Two National Datasets (P11-14.002)

Comparison of Depression and Anxiety in Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis Patients: Analysis of Two National Datasets (P11-14.002)

An Unfortunate Immunological Overlap: A Case Report of Neuromyelitis Optica Compounded with NMDA Receptor Antibody Encephalitis (P11-14.014)

An Unfortunate Immunological Overlap: A Case Report of Neuromyelitis Optica Compounded with NMDA Receptor Antibody Encephalitis (P11-14.014)

Evaluation of Subcortical Pathology and Association with Cognition in Neuromyelitis Optica Spectrum Disorders with Myelin Water Imaging (P10-14.020)

Evaluation of Subcortical Pathology and Association with Cognition in Neuromyelitis Optica Spectrum Disorders with Myelin Water Imaging (P10-14.020)

Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)

Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)

Importance of Bodily Functions in Neuromyelitis Optica Spectrum Disorder from Neurologists’ Perspective (P10-14.018)

Importance of Bodily Functions in Neuromyelitis Optica Spectrum Disorder from Neurologists’ Perspective (P10-14.018)

Relapse And Non-relapse Hospitalizations in Neuromyelitis Optica Spectrum Disorders (NMOSD) (P8-15.004)

Relapse And Non-relapse Hospitalizations in Neuromyelitis Optica Spectrum Disorders (NMOSD) (P8-15.004)

Neurologic Autoimmunity in the Immunodeficient: A Case of Neuromyelitis Optica Developing in an Individual with Common Variable Immunodeficiency (P7-14.002)

Neurologic Autoimmunity in the Immunodeficient: A Case of Neuromyelitis Optica Developing in an Individual with Common Variable Immunodeficiency (P7-14.002)